Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper.
Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper.
复制标题
DOI：
10.3111/13696990903479199
复制
发表时间：
2010-03-01
影响因子：
2.4
通讯作者：
Schoffski, O
中科院分区：
文献类型：
--
作者：
Breitscheidel, L;Stamenitis, S;Schoffski, O
注意事项：次优依从性和未能坚持抗糖尿病治疗具有潜在的经济意义。本研究旨在描述2型糖尿病（T2DM.METHODS）患者依从性差和持续使用抗糖尿病药物对医疗费用或其组成部分的影响。因此，PubMed中未列出但在其他数据库中可用的相关文章可能未纳入当前综述。确定了描述药物降糖治疗依从性和/或持续性的经济后果的研究。在审查的研究的变异性是高的，使其非常难以使它们之间的比较。结果：449篇文章对应的主要搜索算法，12项研究（均在美国进行）符合纳入标准的经济影响的遵守和/或持续治疗的T2 DM护理或其组成部分的总成本。在10项研究中，通过药物拥有率（MPR）评估依从性，其范围为0.52至0.93，取决于方案。在一项研究中评估了持久性。每例T2 DM患者的平均年总成本在研究之间变化，范围为4570美元至17338美元。在7项研究中，药物依从性与总医疗费用呈负相关，而在另外4项研究中，药物依从性与住院费用呈负相关。在一项研究中，增加依从性并没有改变整体healthcare costs.CONCLUSIONS：改善依从性可能会导致T2 DM的总医疗费用的减少，需要在美国以外的国家进行进一步研究，以评估依从性和持续性对T2 DM药物治疗的影响。
OBJECTIVES: Suboptimal compliance and failure to persist with antidiabetes therapies are of potential economic significance. The present research aims to describe the impact of poor compliance and persistence with antidiabetes medications on the cost of healthcare or its components for patients with type 2 diabetes mellitus (T2DM).METHODS: Literature search was conducted in PubMed for relevant articles published in the period between 1 January 2000 and 30 April 2009. Thus, it is possible that relevant articles not listed in PubMed, but available in other databases are not included in the current review. Studies describing economic consequence of compliance and/or persistence with pharmaceutical antidiabetes treatment were identified. The variability in the studies reviewed was high, making it extremely difficult to make a comparison between them.RESULTS: Of 449 articles corresponding to the primary search algorithm, 12 studies (all conducted in USA) fulfilled the inclusion criteria regarding the economic impact of compliance and/or persistence with treatment on the overall cost of T2DM care or its components. Compliance was assessed via medication possession ratio (MPR) in ten studies, where it ranged from 0.52 to 0.93 depending on regimen. Persistence was assessed in one study. Mean total annual costs per T2DM patient varied between the studies, ranging from $4570 to $17338. In seven studies, medication compliance was inversely associated with total healthcare costs, while in four other studies inverse associations between medication compliance and hospitalisation costs were reported. In one study increased adherence did not change overall healthcare costs.CONCLUSIONS: Improved compliance may lead to reductions of the total healthcare costs in T2DM, Further research is needed in countries other than the US to assess impact of compliance and persistence to pharmacotherapy on T2DM costs in country-specific settings.